Other analysts see an opportunity for generic rivals. Indeed, Doug Booth, CEO of a division of Iceland-based Actavis Group, the fourth-largest maker of private label drugs, says his company has ramped
up its manufacturing to five times the capacity versus earlier this year, for clients such as CVS, Walgreens and Wal-Mart.
Still other observers, such as Brand Keys' Robert Passikoff, say we shouldn't count J&J down for the count just yet, even as rivals steal some share in the short term. The venerable brands have a high degree of loyalty, he says. "It's six times more likely that consumers will give them the benefit of doubt and buy them again," he avers.